Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Favipiravir induces HuNoV viral mutagenesis and infectivity loss with clinical improvement in immunocompromised patients.
Kreins AY, Roux E, Pang J, Cheng I, Charles O, Roy S, Mohammed R, Owens S, Lowe DM, Brugha R, Williams R, Howley E, Best T, Davies EG, Worth A, Solas C, Standing JF, Goldstein RA, Rocha-Pereira J, Breuer J. Kreins AY, et al. Among authors: standing jf. Clin Immunol. 2024 Feb;259:109901. doi: 10.1016/j.clim.2024.109901. Epub 2024 Jan 12. Clin Immunol. 2024. PMID: 38218209 Free article.
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease.
Gbinigie O, Ogburn E, Allen J, Dorward J, Dobson M, Madden TA, Yu LM, Lowe DM, Rahman N, Petrou S, Richards D, Hood K, Patel M, Saville BR, Marion J, Holmes J, Png ME, Hayward G, Lown M, Harris V, Jani B, Hart N, Khoo S, Rutter H, Chalk J, Standing JF, Breuer J, Lavallee L, Hadley E, Cureton L, Benysek M, Andersson MI, Francis N, Thomas NPB, Evans P, van Hecke O, Koshkouei M, Coates M, Barrett S, Bateman C, Davies J, Raymundo-Wood I, Ustianowski A, Nguyen-Van-Tam J, Carson-Stevens A, Hobbs R, Little P, Butler CC. Gbinigie O, et al. Among authors: standing jf. BMJ Open. 2023 Aug 7;13(8):e069176. doi: 10.1136/bmjopen-2022-069176. BMJ Open. 2023. PMID: 37550022 Free PMC article.
Respiratory syncytial virus infections in adults: a narrative review.
Wildenbeest JG, Lowe DM, Standing JF, Butler CC. Wildenbeest JG, et al. Among authors: standing jf. Lancet Respir Med. 2024 Oct;12(10):822-836. doi: 10.1016/S2213-2600(24)00255-8. Epub 2024 Sep 9. Lancet Respir Med. 2024. PMID: 39265602 Review.
Correction: Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE).
Smith TA, Hoyo-Vadillo C, Adom AA, Favari-Perozzi L, Gastine S, Dehbi HM, Villegas-Lara B, Mateos E, González YSP, Navarro-Gualito MD, Cruz-Carbajal AS, Cortes-Vazquez MA, Bekker-Méndez C, Aguirre-Alvarado C, Aguirre-Gil G, Delgado-Pastelin L, Owen A, Lowe D, Standing J, Escobedo J. Smith TA, et al. Trials. 2023 May 22;24(1):347. doi: 10.1186/s13063-023-07364-3. Trials. 2023. PMID: 37218017 Free PMC article. No abstract available.
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial.
Harris V, Holmes J, Gbinigie-Thompson O, Rahman NM, Richards DB, Hayward G, Dorward J, Lowe DM, Standing JF, Breuer J, Khoo S, Petrou S, Hood K, Ahmed H, Carson-Stevens A, Nguyen-Van-Tam JS, Patel MG, Saville BR, Francis N, Thomas NPB, Evans P, Dobson M, Png ME, Lown M, van Hecke O, Jani BD, Hart ND, Butler D, Cureton L, Patil M, Andersson M, Coates M, Bateman C, Davies JC, Raymundo-Wood I, Ustianowski A, Yu LM, Hobbs FDR, Little P, Butler CC; PANORAMIC Trial Collaborative Group. Harris V, et al. Among authors: standing jf. Lancet Infect Dis. 2024 Sep 9:S1473-3099(24)00431-6. doi: 10.1016/S1473-3099(24)00431-6. Online ahead of print. Lancet Infect Dis. 2024. PMID: 39265595 Free article.
Named entity recognition of pharmacokinetic parameters in the scientific literature.
Gonzalez Hernandez F, Nguyen Q, Smith VC, Cordero JA, Ballester MR, Duran M, Solé A, Chotsiri P, Wattanakul T, Mundin G, Lilaonitkul W, Standing JF, Kloprogge F. Gonzalez Hernandez F, et al. Among authors: standing jf. Sci Rep. 2024 Oct 8;14(1):23485. doi: 10.1038/s41598-024-73338-3. Sci Rep. 2024. PMID: 39379460 Free PMC article.
Efficient in vitro assay for evaluating drug efficacy and synergy against emerging SARS-CoV-2 strains.
Woodall M, Ellis S, Zhang S, Kembou-Ringert J, Kite K-A, Buggiotti L, Jacobs AI, Agyeman AA, Masonou T, Palor M, McHugh TD, Breuer J, Standing JF, Smith CM. Woodall M, et al. Among authors: standing jf. Antimicrob Agents Chemother. 2024 Dec 17:e0123324. doi: 10.1128/aac.01233-24. Online ahead of print. Antimicrob Agents Chemother. 2024. PMID: 39688407 Free article.
Population pharmacokinetic modeling of ceftriaxone in cerebrospinal fluid in children: should we be using once- or twice-daily dosing for meningitis?
Boast A, Zhang W, Soeorg H, Gonis G, Di Carlo A, Daley A, Curtis N, McWhinney B, Ungerer JPJ, Lei A, Standing JF, Gwee A. Boast A, et al. Among authors: standing jf. Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0074724. doi: 10.1128/aac.00747-24. Epub 2024 Oct 8. Antimicrob Agents Chemother. 2024. PMID: 39377581
137 results